New dosing strategy aims to make cancer treatment more tolerable
NCT ID NCT05263050
Summary
This study is testing a more flexible way to give the cancer drug cabozantinib to people with advanced kidney cancer or neuroendocrine tumors. The goal is to see if adjusting the dose up or down based on how patients feel can help them stay on treatment longer with fewer severe side effects. Some patients will receive the drug alone, while others with kidney cancer will receive it in combination with another immunotherapy drug called nivolumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.